

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Furosemide micro-pump for treating oedema associated with heart failure ID1061

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • ScPharmaceuticals (furosemide micro-pump) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action Heart • British Cardiac Patients Association • Cardiovascular Care Partnership • Circulation Foundation • HEART UK • Muslim Council of Britain • Network of Sikh Organisations • Pumping Marvellous Foundation • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Association for Nursing in Cardiovascular Care • British Cardiovascular Society • British Geriatrics Society • British Heart Foundation • British Society for Heart Failure • Royal College of Emergency Medicine • Royal College of General Practitioners • Royal College of Nursing • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Cardiological Science & Technology • Society for Vascular Nurses • Society for Vascular Technology • UK Health Forum • UK Clinical Pharmacy Association 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British Cardiovascular Industry Association • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (furosemide) • Actavis (furosemide, bendroflumethiazide) • Aurobindo Pharma – Milphram (furosemide) • Beechmere Pharmaceuticals (bendroflumethiazide) • Concordia International (furosemide) • Hameln Pharmaceuticals (furosemide) • International Medication Systems (furosemide) • Leo Laboratories (bumetanide) • Meda Pharmaceuticals (torasemide) • Orion Pharma(furosemide)

National Institute for Health and Care Excellence
Matrix for the proposed technology appraisal of furosemide micro-pump for treating oedema associated with heart failure [ID1061]

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Vascular Society of Great Britain and Ireland <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS Ipswich and East Suffolk CCG • NHS Southwark CCG • Welsh Government 	<ul style="list-style-type: none"> • Pinewood Healthcare (furosemide) • Rosemont Pharmaceuticals (furosemide) • Sanofi (furosemide) • Sovereign Medical (bendroflumethiazide) • Wockhardt UK (furosemide) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Society for Cardiovascular Research • Cardiac and Cardiology Research Dept, Barts • Central Cardiac Audit Database • Cochrane Heart Group • European Council for Cardiovascular Research • MRC Clinical Trials Unit • National Centre for Cardiovascular Preventions and Outcomes • National Institute for Health Research • Wellcome Trust <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.